PG电子黄金城夺宝

News Center

Share the latest news with you

News Center

Share the latest news with you

2023-11-08 • Press Release

IMPACT Therapeutics Presented the Clinical Data for Senaparib as First-line Maintenance Therapy in Advanced Ovarian Cancer Patients at IGCS Annual Global Meeting 2023 as a Plenary oral Presentation

View details
2023-10-24 • Press Release

IMPACT Therapeutics presented preliminary clinical data of WEE1 inhibitor IMP7068 at ESMO Congress 2023

View details
2023-10-23 • Press Release

IMPACT Announces Presentation of the Preliminary Clinical Data for Senaparib in BRCA1/2 Mutated Recurrent Platinum Sensitive Ovarian Cancer and ATR Inhibitor IMP9064 Monotherapy Dose Escalation of FIH Study at the ESMO 2023

View details
2023-10-20 • Press Release

IMPACT Therapeutics Presented Pivotal Phase 3 Clinical Data for Senaparib as First-line Maintenance Therapy in Advanced Ovarian Cancer Patients at ESMO Congress 2023 as a Proffered Late-Breaking Paper Presentation

View details
2023-09-29 • Press Release

IMPACT Therapeutics to present Ph3 pivotal clinical trial data of Senaparib (IMP4297) as Maintenance Treatment in Patients with Advanced Ovarian Cancer at the 2023 ESMO Congress as Late-Breaking Abstract

View details
2023-09-25 • Press Release

IMPACT Therapeutics Announces IND Clearance from U.S. FDA Enabling Phase 1 Initiation for Highly Selective PARP1 Inhibitor, IMP1734

View details
2023-09-01 • Press Release

IMPACT Therapeutics Announces Senaparib NDA Acceptance by the NMPA for first-line Maintenance Treatment of Patients with Advanced Ovarian Cancer

View details

Previous Page 1 2 3 4 5 7 Next Page

Address: 27th Floor, New Bund Times Square, 399 Haiyang West Road, Pudong New Area, Shanghai, China

TEL：021-68411121

Email: info@mulanqingcheng.com

Address: Room 2506, Jingfeng Center, No. 1698 Shuanglong Avenue, Jiangning District, Nanjing

TEL: 025-52283667

Email: info@mulanqingcheng.com

Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备86821482号互联网药品信息证书编号:(沪)-非经营性-2025-0012 / Clinical Trial Privacy Notice /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement

PG电子黄金城夺宝